Maxcyte Share Discussion Threads

[adamb1978] 08/8/2024 02:58

Yes, good set of figures. H1 seems to be moving things back on track:

- core revenue growing again if you like at hoh figures
- 5 new SPLs signed in H1
- better opex control than ever seen by them
- conservative guidance

Very long-term play so quarterly figures are less meaningful but good nonetheless.

[edwardt] 07/8/2024 07:07

Decent numbers...

[sword77] 11/7/2024 21:06

Yes, after the CEO buying, going down below 4 was a real surprise for me. I always sell above 5 and buy below 4. But always keep a core position for the longrun.

[junior21] 11/7/2024 19:11

Very volatile of late. Part of me was hoping we headed back to $3 so I could pick up more but doesn't seem to last long below $4

[sword77] 11/7/2024 17:33

No, don't think that's insider trading, many biotechnology stocks are up

[adamb1978] 11/7/2024 16:44

Big jump pre-close. Maybe some announcement coming after the US market closes?

[sword77] 11/6/2024 13:48

So we can expect numbers track in the right direction?

[sword77] 11/6/2024 13:47

Yes, nearly half a mio usd, not bad

[junior21] 11/6/2024 12:00

Big vote of confidence by the CEO with that purchase. Not used to seeing director buys here!

[davep4] 16/5/2024 20:43

Unfortunately I don’t Adam.

[adamb1978] 11/5/2024 12:54

Hi Davep4

Do you have access to William Blair research so can let us know what they're saying about Casgevy forecasts longer-term?

Some quick searches for the same. This says >$1bn by 2026:

hxxps://www.morningstar.com/company-reports/1222511-crispr-earnings-commercial-launch-of-casgevy-is-underway-positive-outlook-and-shares-undervalued?listing=0P00018U6X

This is slightly older but gives $1bn by 2027 and $2.2bn in 2030 and after:

hxxps://www.statnews.com/2023/11/16/crispr-vertex-sickle-cell-beta-thalassemia-casgevy-approval/

So are we potentially looking at $30m royalties in 2026/7, and $66m in 2030?

Adam

[junior21] 08/5/2024 18:16

Is strange how there wasn't much after hours action last night, but I'm not complaining!

[adamb1978] 08/5/2024 13:56

Timing driven by US opening, but yes!

[junior21] 08/5/2024 13:49

Yes, thanks davep4.

Nice surprise re delayed reaction to results!

[adamb1978] 08/5/2024 08:14

Thanks. Thats helpful

[davep4] 08/5/2024 07:48

William Blair currently expects Casgevy to generate sales of $84.4 million for the full year, so approx $2.5m, (if 3% is correct).

[adamb1978] 08/5/2024 07:31

falls right through to the bottom line though. Zero cost against it

[junior21] 08/5/2024 07:19

I remember reading that it was 3% so roughly $60k. Unlikely to be meaningful amounts this year, but I'd like to see how quickly it ramps up.

[adamb1978] 08/5/2024 06:43

Yes Junior. They said on the call that they wont include any revenue from it in thieir guidance til its absolutely certain, so not sure when that will be. Any idea what they would get per patient?

[junior21] 07/5/2024 22:21

hxxps://www.fiercepharma.com/pharma/vertex-edges-out-bluebird-sickle-cell-gene-therapy-launch-cystic-fibrosis-franchise

Just found this. Vertex currently started on 5 patients. Will be interesting to see what contribution if any we get in the next two quarters

[junior21] 07/5/2024 22:02

Thanks Adam. Just seen that bluebird bio have had their first patient for the sickle cell therapy. Vertex declined to comment on whether they've started yet. Interesting to read the bluebird one costs $3.1m

[adamb1978] 07/5/2024 21:48

I think so. Have a look on their website

[junior21] 07/5/2024 21:36

Sensible approach to take.

Can the call be listened back to?

[adamb1978] 07/5/2024 20:52

Just listened to the Q1 conf call:

- they're clearly sandbagging the guidance, possibly understandably given 2023. Perhaps might not transformational (excl Vertex) but I'd have thought that 10%-15% core revenue growth is possibly a better bet than 0%-5%
- confidence coming back into the customer base, with a number of them having raised capital in Q1
- Forecasts exclude anything from the Vertex therapy as too tough to forecast.

Welcome relief to have Q1 looking better than the awful 2023